Investigational drug · Phase 3
arboplatin
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Platinum-sensitive Recurrent Ovarian Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "arboplatin"
First trial start
2026
Nov 1, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "arboplatin", any sponsor or status.
Conditions studied
As listed on its trial records.
- Platinum-sensitive Recurrent Ovarian Cancer
Approved drugs for the same conditions: Ovarian cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "arboplatin" as an intervention, largest first.
- Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian CancerPivotal-lookingNot yet recruiting
Hansoh BioMedical R&D CompanyIndustry
NCT07821606 · 460 participants (planned) · Start Nov 1, 2026 · Primary completion Dec 30, 2029
Drug: HS-20089+Bevacizumab; Dose 2:arboplatin+Paclitaxel+Bevacizumab and 2 more · For: Platinum-sensitive Recurrent Ovarian Cancer
Sites: Hefei, China; Beijing, China; Chongqing, China · 39 sites in all
- Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLCPivotal-lookingStatus unknown
The First Affiliated Hospital of Henan University of Science and TechnologyAcademic, hospital or other
NCT05209256 · 90 participants (planned) · Start Mar 1, 2022 · Primary completion Jan 2024
Drug: Chemotherapy; Alflutinib plus chemotherapy · For: NSCLC
SanofiSanofi (SNY)
NCT00612495 · 31 participants · Start Jan 2001
Drug: oxaliplatin, 5 FU · For: Endometrial Cancer
Sites: Paris, France
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Platinum-sensitive Recurrent Ovarian Cancer
- HS-20089Phase 33 trials
Hansoh BioMedical R&D Company · Ovarian Cancer, Platinum-sensitive Recurrent Ovarian Cancer, Fallopian Tube Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.